SIX Swiss Exchange

ARGE GUBRI, a joint venture led by Implenia, wins contract to renovate the Gubrist tunnel

Retrieved on: 
Wednesday, April 13, 2022
Lead, Gubrist Tunnel, Investor relations, Total, CHF, Occupational Safety and Health Act 1994, Group, SIX Swiss Exchange, ARGE, Corporate communication, Safety, Partnership, Investor, Tunnel, Construction, Implenia, Nadia Fares Anliker, Opfikon

The ARGE GUBRI joint venture, a partnership between Implenia (40%, lead), Walo Bertschinger (30%) and Anliker (30%), has won the contract from the Federal Roads Administration (FEDRA) for the third section of this renovation.

Key Points: 
  • The ARGE GUBRI joint venture, a partnership between Implenia (40%, lead), Walo Bertschinger (30%) and Anliker (30%), has won the contract from the Federal Roads Administration (FEDRA) for the third section of this renovation.
  • The total contract is worth CHF 184 million, of which Implenia's share is approximately CHF 74 million.
  • This new contract is a good strategic fit for Implenia, whose Division Civil Engineering focuses on large, complex infrastructure projects.
  • The Gubrist Tunnel is one of the busiest road tunnels in Switzerland and the two existing tubes have been in operation since 1985 (image: (c)FEDRA).

Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and lisavanbulin at AACR Annual Meeting

Retrieved on: 
Wednesday, April 13, 2022
Tubulin, Cell proliferation, Infection, Isavuconazonium, EB1, Population, FGFR, Squamous cell carcinoma, Paclitaxel, Merck & Co., Research, Mycosis, Skin cancer, PD-L1, Human, Brain, Glioblastoma, Patient, ICCA, SIX Swiss Exchange, Merck, FGFR1, FGFR2, SAC, Communication, TTK, Maintenance, Roche, Colorectal cancer, Chromosome, PLK1, Neoplasm, Safety, Large-cell lung carcinoma, MCI, Epithelium, Cell division, Cancer, Breast, Cholangiocarcinoma, Medulloblastoma, Therapy, Mitosis, Targeted molecular therapy for neuroblastoma, Vaccine, Pharmaceutical industry, Medical imaging, EU, CSF1R

The compound is a unique dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1).

Key Points: 
  • The compound is a unique dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1).
  • Both kinases collaborate in activating the mitotic spindle assembly checkpoint (SAC), a cell division mechanism regulating correct chromosome alignment and segregation.
  • BAL0891 has shown anti-proliferative activity across diverse tumor cell lines in vitro and single agent efficacy in in-vivo models of solid human cancers.
  • Derazantinib, lisavanbulin and BAL0891 and their uses are investigational and have not been approved by a regulatory authority for any use.

Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study

Retrieved on: 
Wednesday, April 13, 2022
Protein, ADX71149, Nasdaq, Clinical trial, Dipraglurant, Allosteric regulation, PTSD, Glutamate (neurotransmitter), Lists of diseases, MD, Psychosis, Dyskinesia, GABAB, Drug discovery, Dystonia, Patient, SIX Swiss Exchange, LR, PAM, Janssen Pharmaceuticals, Trial of the century, Blepharospasm, Glutamate receptor, American depositary receipt, L-DOPA, Safety, NAM, Epilepsy, Neurodegeneration, Glutamic acid, Therapy, Spasms, Pharmaceutical industry

Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric modulation to downregulate the neurotransmission believed to cause blepharospasm.

Key Points: 
  • Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric modulation to downregulate the neurotransmission believed to cause blepharospasm.
  • A total of 15 patients have been enrolled into this double-blind, placebo controlled Phase 2a feasibility study.
  • The primary objective of the study is to evaluate the safety and tolerability of dipraglurant in patients administered with 50mg and 100mg doses.
  • The effects on the severity and frequency of blepharospasm signs and symptoms using objective measures, clinical ratings and patient reported outcomes will also be evaluated as secondary endpoints.

Cyberattack on parts of the Baloise Group's IT infrastructure

Retrieved on: 
Wednesday, April 13, 2022
LTD, Group, SIX Swiss Exchange, Heart, Insurance, Solution, Safety, Risk management, Bâloise

On 11 April, Baloise detected a cyberattack on parts of its IT infrastructure, primarily systems of Basler Germany.

Key Points: 
  • On 11 April, Baloise detected a cyberattack on parts of its IT infrastructure, primarily systems of Basler Germany.
  • According to the latest information, no company data or customer data has been stolen and no systems have been encrypted.
  • Baloise is still working to deal with the situation with support from external experts.
  • We will continue to do everything we can to protect Baloise and the data of its customers and partners from such attacks.

SoftwareONE Named Flexera North American Partner of the Year for the Sixth Consecutive Year

Retrieved on: 
Tuesday, April 12, 2022
Networks, Internet, Data Management, Technology, Software, Application lifecycle management, DSC, ITAM, Â, Software, VP, Automation, Organization, Digital supply chain, SAM, Technology, SLM, SIX Swiss Exchange, SWON, Solution, General manager, Intelligence, IP, Partnership, Software as a service, Video game console, Online shopping, SoftwareONE

SoftwareONE, a leading global provider of end-to-end software and cloud technology solutions, is honored to announce that we have been named the North American Flexera Partner of the Year for 2022 for the sixth consecutive year.

Key Points: 
  • SoftwareONE, a leading global provider of end-to-end software and cloud technology solutions, is honored to announce that we have been named the North American Flexera Partner of the Year for 2022 for the sixth consecutive year.
  • SoftwareONE was named the North American Partner of the Year for its superior service in software asset management (SAM).
  • SoftwareONE is at the forefront of enabling digital transformation so customers can modernize their applications from on-premises to the cloud.
  • It is a great honor to receive this recognition from Flexera, said Ashley Gaare, President, SoftwareONE North America.

MEDIA RELEASE (PDF) Kinarus Receives Positive Recommendation from DSMB to Continue Phase 2 Trial in COVID-19

Retrieved on: 
Tuesday, April 12, 2022
Pioglitazone, Ventilation, Hospital, Peroxisome proliferator-activated receptor gamma, World Health Organization, WHO, Trial of the century, MAPK, Swiss Federal Nuclear Safety Inspectorate, Mortality, Data monitoring committee, Vaccine, Idiopathic pulmonary fibrosis, World, EudraCT, Public health, COVID-19, PPAR, Disease, Program, DSMB, Extracorporeal membrane oxygenation, ECMO, ICU, Idiopathic disease, Acquisition, Patient, SIX Swiss Exchange, Pharmaceutical industry, Muthiri kinaru, Omicron

Phase 2 trial assesses Kinarus' oral therapy, KIN001, to reduce mortality and the need for respiratory support in hospitalized COVID-19 patients

Key Points: 
  • Phase 2 trial assesses Kinarus' oral therapy, KIN001, to reduce mortality and the need for respiratory support in hospitalized COVID-19 patients
    Basel, Switzerland, April 12, 2022.
  • Kinarus AG ('Kinarus'), a Swiss clinical-stage biopharmaceutical company announced today that the independent Data and Safety Monitoring Board ('DSMB') has completed its interim safety review of the Kinarus Phase 2 KINETIC study.
  • DSMB recommends that the study continue as designed with Kinarus' oral therapy, KIN001, for treating hospitalized patients with severe COVID-19.
  • The unblinded interim safety review by the DSMB was conducted after the enrollment and completion of the first 40 patients.

SoftwareONE publishes agenda for 2022 Annual General Meeting

Retrieved on: 
Tuesday, April 12, 2022
Proxy, Audit committee, SoftwareONE, TEL, Board, Zalando, Bossard Holding AG, Board of directors, Intelligence, Software, Federal Council (Switzerland), CHF, Technology, SWON, COVID-19, Annual general meeting, News, SIX Swiss Exchange, Annual, Holding company, Management, Director

Stans, Switzerland I 12 April 2022 - SoftwareONE Holding AG, a leading global provider of end-to-end software and cloud technology solutions, today published the agenda and the proposals of the Board of Directors for its upcoming Annual General Meeting, which will be held on 5 May 2022 without the physical presence of shareholders.

Key Points: 
  • Stans, Switzerland I 12 April 2022 - SoftwareONE Holding AG, a leading global provider of end-to-end software and cloud technology solutions, today published the agenda and the proposals of the Board of Directors for its upcoming Annual General Meeting, which will be held on 5 May 2022 without the physical presence of shareholders.
  • The invitation and full agenda for the 2022 Annual General Meeting is available here on SoftwareONE's website.
  • The Annual General Meeting will be held without in-person attendance of shareholders in accordance with article 27 of the COVID-19 Ordinance 3 of the Swiss Federal Council.
  • Shareholders of SoftwareONE may exercise their rights at the Annual General Meeting on 5 May 2022 exclusively through the independent proxy.

Annual General Meeting of Julius Baer Group Ltd.

Retrieved on: 
Tuesday, April 12, 2022
SLI, Nomination, Executive, Eunice, SIX Swiss Exchange, Financial statement, AGM, Board, Remuneration, Julia gens, Statutory auditor, Board of directors, Consolidated, CHF, KPMG, Swiss Leader Index, Share repurchase, RTÉ Executive Board, Financial compensation, Law, Professional Football Compensation Committee, Annual, Financial adviser, Audit, Management, Holding company, Director

Zurich, 12 April 2022 - At today's Annual General Meeting of Julius Baer Group Ltd. the shareholders passed all agenda items and proposals submitted by the Board of Directors.

Key Points: 
  • Zurich, 12 April 2022 - At today's Annual General Meeting of Julius Baer Group Ltd. the shareholders passed all agenda items and proposals submitted by the Board of Directors.
  • In detail, the Annual General Meeting 2022 of Julius Baer Group Ltd. passed the following resolutions:
    The Financial Statements and Consolidated Financial Statements 2021 were approved and the Remuneration Report 2021 was approved in a consultative vote.
  • Marc Nater, Wenger Plattner Attorneys at Law, Kuesnacht, was elected as independent representative until the end of the next Ordinary Annual General Meeting in 2023.
  • Julius Baer is the leading Swiss wealth management group and a premium brand in this global sector, with a focus on servicing and advising sophisticated private clients.

The Annual General Meeting of Valora Holding AG approves all proposals by the Board of Directors

Retrieved on: 
Tuesday, April 12, 2022
OK, Industry, Exercise, Proxy, Sale, Group, Board, NYSE, Sunday Press Books, Mass meeting, Annual general meeting, ETA, Board of directors, SIX Swiss Exchange, Tesla, Vocational university, IKEA, CHF, Business administration, Artificial intelligence, National Executive Board of the Boy Scouts of America, Applied science, COVID-19, EMEA, University, Silicon, Annual, Security (finance), Holding company, Management, Mytheresa, Valora, Director

2,416,031 registered shares or 55.03% of the share capital represented at today's Annual General Meeting of Valora Holding AG.

Key Points: 
  • 2,416,031 registered shares or 55.03% of the share capital represented at today's Annual General Meeting of Valora Holding AG.
  • The Annual General Meeting of Valora Holding AG, chaired by Franz Julen, the outgoing Chairman of the Board of Directors, took place in Basel today.
  • The shareholders also elected the previous Vice-Chairman Sascha Zahnd as the new Chairman of the Board of Directors of Valora Holding AG.
  • At its inaugural meeting immediately following the Annual General Meeting, the Board of Directors elected Insa Klasing as the new Vice-Chairman.

Baloise shares its know-how with start-up founders

Retrieved on: 
Tuesday, April 12, 2022
Marketing, Heart, Group, SIX Swiss Exchange, Suggestion, Safety, Solution, LTD, Executive Committee, Social media, Insurance, Online shopping, Bâloise

Founders constantly face all manner of questions and challenges and few young start-ups have the very broad expertise required to tackle them.

Key Points: 
  • Founders constantly face all manner of questions and challenges and few young start-ups have the very broad expertise required to tackle them.
  • As part of its Simply Safe corporate strategy, Baloise has collaborated with its customers to develop ideas for how Baloise can give emerging entrepreneurs access to the valuable know-how of its experts.
  • Baloise is extending this offer to all corporate customers who have founded a new business in the past three years.
  • Bloise Holding Ltd shares are listed in the main segment of the SIX Swiss Exchange.